Prothrombotic disturbances of hemostasis of patients with severe COVID-19

Thrombosis research, Vol. 197, p. 20-23 (2021)
Hardy, M, Michaux, I, Lessire, S, Douxfils, J, Dogné, J-M, Bareille, M, Horlait, G, Bulpa, P, Chapelle, C, Laporte, S, Testa, S, Jacqmin, H, Lecompte, T, Dive, A & Mullier, F 2021, ' Prothrombotic disturbances of hemostasis of patients with severe COVID-19 : A prospective longitudinal observational study ', Thrombosis Research, vol. 197, pp. 20-23 . https://doi.org/10.1016/j.thromres.2020.10.025
Thrombosis research, Vol. 197, p. 20-23 (2020)
Thrombosis Research

Male; medicine.medical_specialty; Thrombin generation; Time Factors; Coronavirus disease 2019 (COVID-19); COVID19; PAI-1; Letter to the Editors-in-Chief; D-dimers; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; AT, antithrombin; Fibrin Fibrinogen Degradation Products; RT-PCR, reverse transcription polymerase chain reaction; PT, prothrombin time; Plasminogen Activator Inhibitor 1; medicine; Humans; Thrombophilia; UFH, unfractionated heparin; Prospective Studies; PAI-1, plasminogen activator inhibitor 1; IQR, interquartile range; ISTH, International Society on Thrombosis and Haemostasis; COVID19, coronavirus disease 2019; Hemostasis; Biological Variation, Individual; Factor VIII; business.industry; DVT, deep vein thrombosis; SARS-CoV-2; Fibrinolysis; Thrombin; Anticoagulants; COVID-19; Fibrinogen; Hematology; LMWH, low molecular weight heparins; ICU, intensive care unit; C-Reactive Protein; Intensive care; Emergency medicine; PE, pulmonary embolism; CRP, C-reactive protein; Observational study; Female; Blood Coagulation Tests; business

English